Stockscreener 앱 받기
2.32
8.41%
0.18
시장 영업 전:
2.32
전일 마감가:
$2.14
열려 있는:
$2.17
하루 거래량:
611.24K
Relative Volume:
0.33
시가총액:
$147.74M
수익:
-
순이익/손실:
$-30.05M
주가수익비율:
-3.6773
EPS:
-0.6309
순현금흐름:
$-27.71M
1주 성능:
+8.92%
1개월 성능:
+64.54%
6개월 성능:
-7.20%
1년 성능:
-40.51%
1일 변동 폭
$2.16
$2.3391
1주일 범위
$2.08
$2.44
52주 변동 폭
$0.41
$4.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
명칭
Tuhura Biosciences Inc
전화
813-875-6600
주소
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.32 | 147.74M | 0 | -30.05M | -27.71M | -0.6309 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | Citizens | Mkt Outperform |
| 2025-03-03 | 개시 | H.C. Wainwright | Buy |
| 2024-12-19 | 개시 | Rodman & Renshaw | Buy |
| 2024-11-05 | 개시 | Maxim Group | Buy |
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
Tuhura Biosciences, Inc. 2025 Annual Report: Financial Results, Research & Development Expenses, and Key Business Highlights - Minichart
TuHURA Biosciences (NASDAQ: HURA) updates Kineta merger pro forma loss to $34.6M - Stock Titan
TuHURA Biosciences (NASDAQ: HURA) details 2025 loss and cash runway - Stock Titan
HURA Stock Price, Quote & Chart | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
Citizens initiates TuHURA Biosciences stock with outperform rating By Investing.com - Investing.com South Africa
Citizens initiates TuHURA Biosciences stock with outperform rating - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP By Investing.com - Investing.com Nigeria
Tuhura Biosciences secures $50 million credit facility, extends cash runway to 2028 - MSN
TuHURA Biosciences secures $50M credit facility from affiliate By Investing.com - Investing.com India
HURA (TuHURA Biosciences Inc.) posts 28.2 percent negative Q4 2025 EPS surprise, with shares falling 1.35 percent today.Community Risk Signals - UBND thành phố Hải Phòng
TuHURA Biosciences secures $50M credit facility from affiliate - Investing.com
TuHURA Biosciences Secures $50 Million Credit Facility - TipRanks
TuHURA Biosciences (Nasdaq: HURA) adds $50M credit line and IFx-2.0 royalty - Stock Titan
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 - PR Newswire
TuHURA Biosciences Advances Cancer Drug Trials Following 2025 Results - HarianBasis.co
5 Unstoppable Stocks That Could Double Your Money - Insider Monkey
Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money? - Insider Monkey
TuHURA Biosciences (HURA) Stock Abandons TuHURA Biosciences (HURA) Stock (Risk Aversion) 2026-04-16Momentum Signals - UBND thành phố Hải Phòng
Rodman & Renshaw initiates TuHURA Biosciences stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw Initiates TuHURA Biosciences(HURA.US) With Buy Rating, Announces Target Price $7 - Moomoo
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rodman & Renshaw initiates TuHURA Biosciences stock with buy rating - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Raised to Hold at Wall Street Zen - MarketBeat
Equities Analysts Set Expectations for HURA FY2026 Earnings - MarketBeat
Brookline Capital Markets Comments on HURA Q1 Earnings - MarketBeat
Downgrade Watch: What is the target price for TuHURA Biosciences Inc stockWeekly Market Summary & AI Forecasted Stock Moves - baoquankhu1.vn
FY2029 EPS Forecast for TuHURA Biosciences Lifted by Analyst - MarketBeat
HURA.O PE Ratio & Valuation, Is HURA.O Overvalued - Intellectia AI
Aug Rallies: Does TuHURA Biosciences Inc. align with a passive investing strategyTrade Volume Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Hedge Fund Moves: Is TuHURA Biosciences Inc a strong candidate for buy and hold - baoquankhu1.vn
HURA: 2025 Financial Results - Yahoo Finance
TuHURA Biosciences Acquires Kineta in $16.6M Merger and Closes $12.6M Private Placement – Key Details and Financial Impact - Minichart
TuHURA Biosciences approves executive bonuses and salary increases By Investing.com - Investing.com India
TuHURA Biosciences Approves 2025 Executive Compensation Adjustments - TipRanks
TuHURA Biosciences approves executive bonuses and salary increases - Investing.com
Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co. - TradingView
TuHURA (NASDAQ: HURA) $50M ATM equity facility via H.C. Wainwright - Stock Titan
TuHURA awards bonuses to James Bianco and Dan Dearborn, adjusts salaries - TradingView
Kineta deal and $11.5M raise shape TuHURA Biosciences (NASDAQ: HURA) 2025 results - Stock Titan
TuHURA Appoints New SVP of Clinical Operations - Intellectia AI
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - Sahm
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP - Investing.com
Cancer drug developer hires 20-year veteran to run clinical trials - Stock Titan
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
HURA SEC FilingsTuHURA Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Risk: What dividend growth rate does TuHURA Biosciences Inc offer2026 Closing Moves & Detailed Earnings Play Strategies - baoquankhu1.vn
Is TuHURA Biosciences (HURA) Stock a Safe Investment | Price at $1.46, Up 3.19%Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
EPS Watch: Does TuHURA Biosciences Inc stock reflect fundamentals2026 Technical Patterns & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Tuhura Biosciences Inc (HURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):